Product
Walvax PCV13-TT
1 clinical trial
2 indications
Indication
pneumococcal diseaseIndication
InvasiveClinical trial
A Phase 3, Randomized, Blinded, Active-controlled Study to Evaluate the Immunogenicity and Safety of Walvax's 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13-TT) as Compared to Pfizer's 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Co-administered With EPI Vaccines at 2, 4, and 12-15 Months of Age, to Healthy Infants in IndonesiaStatus: , Estimated PCD: 2024-12-01